News & Publications


News


David FogelLife without a stomach:  a patient's perspective on preventative surgery, advancing stomach cancer research

NIH Clinical Center News, Winter 2018

When David Fogel had a stomach, his fast-paced life was focused on expanding Bump 'n Grind, his coffee shop and record store in downtown Silver Spring, and managing a creative agency and two co-working spaces. Incorporated into his busy schedule was raising his two little sons with his wife.  Read more...

The NIH Clinical CenterMembers of the NIH Foregut Team discuss new treatment options for stomach cancer

November 30, 2017

On Wednesday, Nov. 29, 2017, NIH Foregut Team members presented information and answered questions during a webinar on stomach cancer treatment options.  Jeremy Davis, M.D., Staff Clinician in the CCR Thoracic and Gastrointestinal Oncology Branch, and Theo Heller, M.D., Senior Investigator in the National Institute of Diabetes and Digestive and Kidney Diseases, joined David Fogel, a recent total gastrectomy patient, to discuss the latest advancements in treatment. The webinar, “Navigating New Treatment Options for Gastric Cancer: Reaching above and beyond the standard of care,” was facilitated by the NIH Clinical Center and Inspire, a social network for health that connects patients and caregivers in a safe, permission-based manner.  Access the recorded webinar.

 

Esophageal cancer cellsClinical trial looks at new methods of assessing treatment response for esophageal cancer

September 12, 2017

R. Taylor Ripley, M.D., of the Thoracic and Gastrointestinal Oncology Branch is leading a study to determine whether metabolomic signatures or BH3 profiling in biopsy tissues can identify patients who will likely respond well to pre-surgical treatment.  Learn more...

Doctor holding her patient's hands at a bedside.

New clinical trial studies two-part treatment for patients with gastric cancer

May 1, 2017

A new clinical trial is open to test a two-part treatment for stomach cancer that has spread to the peritoneum.  Learn more...

Patient Joel Rodriguez eating french fries with his doctors on a hospital bed.

"They gave me my life back"

March 30, 2017

Nineteen-year-old Joel Rodriguez didn’t think he would be able to eat again. However, a collaboration between surgeons in the Center for Cancer Research (CCR) and the National Institute of Allergy and Infectious Diseases (NIAID) gave that back to him. Rodriquez and his treatment team celebrated the success of their operation with Rodriguez’s food of choice —  cheeseburgers and French fries — in his hospital room. Read More...

The Foregut Cancer team

Foregut cancers get new attention at CCR

March 27, 2017

The new NIH Foregut Team includes experts from a wide range of disciplines. The team hopes to give patients the best possible outcome by working together and sharing their expertise. Read more...

LMB-100 is a targeted immunotherapy that delivers a toxin to cancer cells that make a protein called mesothelin.

New clinical trial combines LMB-100 with nab-paclitaxel for metastatic or locally advanced pancreatic cancer

July 8, 2016

Christine Campo Alewine, Lasker Scholar, in the Laboratory of Molecular Biology is conducting a clinical study for patients with pancreatic cancer using a new immunotoxin drug, called LMB-100. It is a targeted immunotherapy that delivers a toxin to cancer cells that make a protein called mesothelin that is made by most pancreatic cancers. Learn more...

Selected Recent Publications

Bile acid and cigarette smoke enhance the aggressive phenotype of esophageal adenocarcinoma cells by downregulation of the mitochondrial uncoupling protein-2. Xu Y, Feingold PL, Surman DR, Brown K, Xi S, Davis JL, Hernandez J, Schrump DS, Ripley RT. Oncotarget 2017 Nov 10;8(60):101057-101071.

Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes. Kolyvas E, Rudloff M, Poruchynsky M, Landsman R, Hollevoet K, Venzon D, Alewine C. Oncotarget 2017 Feb 7;8(6):9189-9199.

Single cell analysis reveals cancer stem cell heterogeneity in hepatocellular carcinoma. Zheng H, Pomyen Y, Hernandez MO, Li C, Livak F, Tang W, Dang H, Greten TF, Davis JL, Zhao Y, Mehta M, Levin Y, Shetty J, Tran B, Budhu A, Wang XW. Hepatology. 2018 Jan 9. doi: 10.1002/hep.29778. [Epub ahead of print].

Heated intraperitoneal chemotherapy and gastrectomy for gastric cancer in the U.S.: the time is now. Brown ZJ, Hernandez JM, Ripley RT, Davis JL. J Gastrointest Oncol. 2017 Dec;8(6):1109-1113. doi: 10.21037/jgo.2017.09.01. Review.

.